Literature DB >> 477738

Central mediation of the antihypertensive effect of pargyline in spontaneously hypertensive rats.

J A Fuentes, A Ordaz, N H Neff.   

Abstract

The monoamine oxidase (MAO) inhibitor pargyline induced a moderate (about 20 mm Hg) but persistent (48 h) decrease of systolic blood pressure in unanesthetized adult spontaneously hypertensive rats (SHR) but not in normotensive rats. The fall of blood pressure correlated with the blockade of norepinephrine (NE) deamination by brain homogenates. After an intracerebroventricular (icv) injection of 6-hydroxydopamine, which lowered brain NE content by about 70%, pargyline was unable to diminish arterial pressure. Blockade of central alpha-adrenoceptors by treatment with phentolamine (100 microgram icv) could either prevent or reverse the fall of blood pressure in SHR induced by pargylline. Moreover, a low dose of pargyline injected directly into the brain lowered arterial pressure. We conclude that the hypotensive action of pargylline in SHR appears to be the consequence of NE accumulating at an inhibitory alpha-adrenoceptor in brain.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 477738     DOI: 10.1016/0014-2999(79)90099-2

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

Review 1.  Serotonin and blood pressure regulation.

Authors:  Stephanie W Watts; Shaun F Morrison; Robert Patrick Davis; Susan M Barman
Journal:  Pharmacol Rev       Date:  2012-03-08       Impact factor: 25.468

2.  Possible melatonin involvement in the hypotensive effect of MAO inhibitors.

Authors:  G F Oxenkrug; R B McCauley; D J Fontana; I M McIntyre; R L Commissaris
Journal:  J Neural Transm       Date:  1986       Impact factor: 3.575

3.  The role of extraneuronal amine transport systems for the removal of extracellular catecholamines in the rabbit.

Authors:  B Friedgen; R Wölfel; H Russ; E Schömig; K H Graefe
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996 Aug-Sep       Impact factor: 3.000

4.  The effect of clorgyline on noradrenergic function.

Authors:  R J Ross; M Scheinin; P Lesieur; M V Rudorfer; R L Hauger; L J Siever; M Linnoila; W Z Potter
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

5.  Body fat reduction without cardiovascular changes in mice after oral treatment with the MAO inhibitor phenelzine.

Authors:  Christian Carpéné; Josep Mercader; Sophie Le Gonidec; Stéphane Schaak; Jeanne Mialet-Perez; Alexia Zakaroff-Girard; Jean Galitzky
Journal:  Br J Pharmacol       Date:  2018-05-06       Impact factor: 8.739

6.  Chronic clorgyline treatment enhances release of norepinephrine following sympathetic stimulation in the rat.

Authors:  J P Finberg; I J Kopin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-03       Impact factor: 3.000

7.  Treatment with clorgyline and pargyline differentially decreases clonidine-induced hypotension and bradycardia.

Authors:  J S Gutkind; M A Enero
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-09       Impact factor: 3.000

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.